← Leaderboards
Adam P. Geballe
Fred Hutchinson Cancer Research Center
$12,800,633
Attributed
$16,612,432
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$16,612,432 · 9
By mechanism
R01$14,374,432 · 4
R21$1,798,000 · 4
R56$440,000 · 1
Top collaborators
- Michael A Mcvoy11 shared
- Mark R. Schleiss11 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Margaret L Green$653,400
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusVirusViralCellsProteinsGenesGene ExpressionPathway InteractionsProtein Kinase RMutantInfectionInsightResponsePreventDouble-Stranded RnaHost DefenseMutationProtein BiosynthesisMolecularVirus ReplicationImmunocompromised HostInterferonsViral ProteinsLife
Grant awards (42)
Evolution and mechanism of restriction of herpesviruses by MxB$220,000
R21 · FY2024 · AI · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$623,296
R01 · FY2023 · HD
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses$440,057
R01 · FY2023 · AI · contact PI
Evolution and mechanism of restriction of herpesviruses by MxB$264,000
R21 · FY2023 · AI · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$629,164
R01 · FY2022 · HD
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses$440,057
R01 · FY2022 · AI · contact PI
Roles and regulation of polyamines during HCMV infection$170,886
R21 · FY2022 · AI · contact PI
Roles and regulation of polyamines during HCMV infection$49,114
R21 · FY2022 · AI · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$635,993
R01 · FY2021 · HD
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses$443,857
R01 · FY2021 · AI · contact PI
Roles and regulation of polyamines during HCMV infection$264,000
R21 · FY2021 · AI · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$655,748
R01 · FY2020 · HD
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses$455,257
R01 · FY2020 · AI · contact PI
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection$689,044
R01 · FY2019 · HD
Translational Control of Cytomegalovirus Gene Expression$440,000
R56 · FY2018 · AI · contact PI
Translational Control of Cytomegalovirus Gene Expression$440,000
R01 · FY2017 · AI · contact PI
Translational Control of Cytomegalovirus Gene Expression$440,000
R01 · FY2016 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$489,296
R01 · FY2015 · HD
Translational Control of Cytomegalovirus Gene Expression$440,000
R01 · FY2015 · AI · contact PI
Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses$264,000
R21 · FY2015 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$477,070
R01 · FY2014 · HD
Translational Control of Cytomegalovirus Gene Expression$427,353
R01 · FY2014 · AI · contact PI
Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses$220,000
R21 · FY2014 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$514,634
R01 · FY2013 · HD
Translational Control of Cytomegalovirus Gene Expression$402,592
R01 · FY2013 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$461,007
R01 · FY2012 · HD
Translational Control of Cytomegalovirus Gene Expression$423,338
R01 · FY2012 · AI · contact PI
Viral immunomodulation and rational CMV vaccine design$62,659
R01 · FY2012 · HD
Viral immunomodulation and rational CMV vaccine design$479,788
R01 · FY2011 · HD
Translational Control of Cytomegalovirus Gene Expression$423,568
R01 · FY2011 · AI · contact PI
Translational Control of Cytomegalovirus Gene Expression$428,072
R01 · FY2010 · AI · contact PI
Translational Control of Cytomegalovirus Gene Expression$432,617
R01 · FY2009 · AI · contact PI
Translational Control of Cytomegalovirus Gene Expression$432,832
R01 · FY2008 · AI · contact PI
Translational Control of Cytomegalovirus Gene Expression$367,349
R01 · FY2007 · AI · contact PI
Translational Control of Cytomegalovirus Gene Expression$378,321
R01 · FY2006 · AI · contact PI
Translational Control of Cytomegalovirus Gene Expression$387,425
R01 · FY2005 · AI
Translational Control of Cytomegalovirus Gene Expression$383,400
R01 · FY2004 · AI
Translational Control of Cytomegalovirus Gene Expression$387,425
R01 · FY2003 · AI
Translation termination a chemotherapeutic target?$173,000
R21 · FY2002 · CA
TRANSLATIONAL CONTROL OF CYTOMEGALOVIRUS GENE EXPRESSION$346,626
R01 · FY2001 · AI
Translation termination a chemotherapeutic target?$173,000
R21 · FY2001 · CA
TRANSLATIONAL CONTROL OF CYTOMEGALOVIRUS GENE EXPRESSION$336,587
R01 · FY2000 · AI